PF-06412562 3mg BID

DRUG2 trials

Sponsors

Pfizer

Conditions

HealthySchizophrenia

Phase 1

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

TerminatedNCT02306876

Start: 2015-01-19End: 2016-06-14Updated: 2017-08-17

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

CompletedNCT02418819

PfizerSchizophrenia

Start: 2015-04-30End: 2016-10-31Updated: 2019-02-04

Related Papers

A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity

The International Journal of Neuropsychopharmacology2020-02-1212 citations